Related Experiment Videos
Breast cancer and prostaglandins: a new approach to treatment
Abstract:
The effect of the non-steroidal inhibitor of prostaglandin synthesis, flurbiprofen, has been studied on a transplanted mouse mammary tumour of spontaneous origin. Daily administration of 2.5 mg/kg flurbiprofen signficantly reduced the growth of this NC adenocarcinoma transplanted subcutaneously into the right flank of WHT/Ht mice. Histological examination showed that primary tumours excised at 3 weeks from treated mice tended to have a more prominent lymphocytic infiltration. There was a non-significant tendency for mice treated with flurbiprofen alone to survive longer after tumour excision and to develop less local metastases, although scar recurrences seemed unaffected. The effect of adjuvant chemotherapy and local radiotherapy on local metastases and survival time tended to be greater when flurbiprofen was also given. This work supports and extends the basis for prospective clinical trials to evaluate the role of prostaglandins in human cancer and the value of prostaglandin synthesis inhibitors in cancer therapy.
Insights
Flurbiprofen, a non-steroidal inhibitor, significantly reduced mouse mammary tumor growth. This suggests prostaglandin synthesis inhibitors may be valuable in cancer therapy, warranting clinical trials.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Prostaglandins play a role in cancer development and progression.
- Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit prostaglandin synthesis.
Purpose of the Study:
- To investigate the effect of flurbiprofen on a transplanted mouse mammary tumor.
- To evaluate flurbiprofen's potential as an adjuvant cancer therapy.
Main Methods:
- Daily administration of 2.5 mg/kg flurbiprofen to mice with transplanted mammary tumors.
- Subcutaneous tumor implantation in WHT/Ht mice.
- Histological examination of tumors and assessment of survival and metastasis.
Main Results:
- Flurbiprofen significantly reduced tumor growth.
- Increased lymphocytic infiltration observed in tumors from treated mice.
- Tendency for improved survival and reduced local metastases with flurbiprofen, especially when combined with chemotherapy and radiotherapy.
Conclusions:
- Flurbiprofen demonstrates anti-tumor effects in a preclinical model.
- Inhibition of prostaglandin synthesis may be a viable strategy in cancer treatment.
- Further clinical trials are supported to explore prostaglandin synthesis inhibitors in human cancer therapy.